Preparation, characterization, and evaluation of bedaquiline fumarate: ascorbic acid co-crystals with enhanced pharmaceutical and physicochemical properties
Abstract Background Bedaquiline fumarate (BDQ) is an anti-tubercular Biopharmaceutics Classification System (BCS class-II) drug & it has very less solubility. Therefore, an effort has been made to prepare the bedaquiline fumarate co-crystal to improve its physicochemical and pharmaceutical chara...
Saved in:
| Main Authors: | Shital D. Godse, Ranjit B. Mohare, Vishal P. Zambre, Vidhya K. Bhusari, Minal Ghante |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-06-01
|
| Series: | Future Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43094-025-00790-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiac toxicity of fluoroquinolones and bedaquiline
by: G. N. Mozhokinа, et al.
Published: (2019-05-01) -
Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis
by: Xinyang Hu, et al.
Published: (2025-05-01) -
Lymphocyte dynamics in patients with multiple sclerosis who were treated with dimethyl fumarate and subsequently switched to diroximel fumarate
by: Shauna M. Gales, et al.
Published: (2025-06-01) -
Distribution of Minimum Inhibitory Concentrations and Resistance-associated Gene Mutations in Multidrug-resistant Mycobacterium tuberculosis Strains from Southern Türkiye: Insights on Bedaquiline, Delamanid, and Linezolid
by: Huda Ahmed, et al.
Published: (2024-12-01) -
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USA
by: Sophia Woodson, et al.
Published: (2025-06-01)